Daré Bioscience Regains Nasdaq Compliance, Advances Phase 3 Trials

Daré Bioscience (DARE) has provided an update.

Daré Bioscience, Inc. has announced it is back in line with Nasdaq’s continued listing requirements after maintaining a minimum bid price of $1.00 per share for over ten consecutive trading sessions. This success marks the closure of previous compliance concerns with Nasdaq. Additionally, Daré is advancing towards Phase 3 studies of its Sildenafil Cream for treating female sexual arousal disorder, a condition with no FDA-approved treatments to date, while awaiting further FDA guidance on study endpoints and data requirements for a future new drug application.

Learn more about DARE stock on TipRanks’ Stock Analysis page.